在标准标准判断为预后良好的黑色素瘤患者亚群中,使用预后31基因表达谱识别有转移风险的患者
本研究基于3项既往验证研究提供的690例皮肤黑色素瘤患者非重叠队列,评估31基因表达谱(31-GEP)在哨兵淋巴结阴性、I至IIA期及薄(≤1 mm [T1])肿瘤三个低危亚群中的风险预测能力。结果显示31-GEP可独立于传统分期因素识别高危患者,70%发生转移的哨兵淋巴结阴性患者被归为Class 2。
要点
- 31-GEP可将哨兵淋巴结阴性、I至IIA期和薄肿瘤患者中的高危者识别为Class 2。
- 70%发生转移的哨兵淋巴结阴性患者被31-GEP归为Class 2。
- 薄肿瘤中Class 2B生物学患者无复发生存低于Class 1A生物学患者(P < .0001)。
核心结论
- 31-GEP可在哨兵淋巴结阴性、I至IIA期和薄肿瘤的皮肤黑色素瘤低危亚群中识别可能复发或死于黑色素瘤的高危患者。
研究设计与样本
- 3项既往验证研究提供690例具有31-GEP结果、分期信息和生存结局的非重叠皮肤黑色素瘤患者队列,采用Kaplan-Meier和Cox回归分析。
主要发现
- 70%发生转移的哨兵淋巴结阴性患者被31-GEP归为Class 2。
- 薄肿瘤中Class 2B生物学患者无复发生存低于Class 1A生物学患者(P < .0001)。
- 在I至IIA期肿瘤患者中,31-GEP是独立于传统分期因素的风险预测因子。
关键数值与推荐
- 31-GEP将皮肤黑色素瘤患者转移风险分为低危(Class 1,1A表示最低风险)或高危(Class 2,2B表示最高风险)。
局限性
- 诊断跨越多个版本的病理分期标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A substantial number of patients who relapse and die from cutaneous melanoma (CM) are categorized as being at low risk by traditional staging factors. The 31-gene expression profile (31-GEP) test independently stratifies metastatic risk of patients with CM as low (Class 1, with 1A indicating lowest risk) or high (Class 2,with 2B indicating highest risk). OBJECTIVE: To assess risk prediction by the 31-GEP test within 3 low-risk (according to the American Joint Committee on Cancer) populations of patients with CM: those who are sentinel lymph node (SLN) negative, those with stage I to IIA tumors, and those with thin (≤1 mm [T1]) tumors. METHODS: A total of 3 previous validation studies provided a nonoverlapping cohort of 690 patients with 31-GEP results, staging information, and survival outcomes. Kaplan-Meier and Cox regression analysis were performed. RESULTS: The results included the identification of 70% of SLN-negative patients who experienced metastasis as Class 2, the discovery of reduced recurrence-free survival for patients with thin tumors and Class 2B biology compared with that of those with Class 1A biology (P < .0001); and determination of the 31-GEP test as an independent predictor of risk compared with traditional staging factors in patients with stage I to IIA tumors. LIMITATIONS: Diagnoses spanned multiple versions of pathologic staging criteria. CONCLUSIONS: The 31-GEP test identifies high-risk patients who are likely to experience recurrence or die of melanoma within low-risk groups of subpopulations of patients with CM who have SLN-negative disease, stage I to IIA tumors, and thin tumors.
引用
- Gastman BR, Gerami P, Kurley SJ, et al. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. J Am Acad Dermatol. 2018. PMID: 30081113. doi:10.1016/j.jaad.2018.07.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。